Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 4/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | TEK | Q02763 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30450535 | 1.00 | EPHB4 (0.34) | EPHB4KDRTEKPARP1 | |
| SCHEMBL19922759 | 0.90 | EPHB4 (0.32) | EPHB4 | |
| SCHEMBL19922748 | 0.87 | PARP1 (0.33) | EPHB4PARP1 | |
| SCHEMBL30450190 | 0.86 | EPHB4 (0.35) | EPHB4KDRTEK | |
| SCHEMBL19922742 | 0.86 | EPHB4 (0.35) | EPHB4KDRTEK | |
| SCHEMBL19922747 | 0.85 | EPHB4 (0.30) | EPHB4 | |
| SCHEMBL19922770 | 0.85 | PARP1 (0.30) | PARP1 | |
| SCHEMBL19922749 | 0.84 | EPHB4 (0.37) | EPHB4KDRTEK | |
| SCHEMBL26415379 | 0.83 | AR (0.34) | EPHB4 | |
| SCHEMBL19922990 | 0.82 | AR (0.33) | EPHB4KDRTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326761-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-11731977-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731977-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731977-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-3872080-B1 | FUSED BICYCLIC SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3872080-B1 | FUSED BICYCLIC SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20220009937-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-13 | — | — | US | disclosed |
| US-20220009937-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-13 | — | — | US | disclosed |
| US-20210177846-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | TISENTO THERAPEUTICS INC. | 2021-06-17 | — | — | US | disclosed |
| EP-3507291-B1 | FUSED BICYCLIC SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10472363-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472363-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190248794-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2019-08-15 | — | — | US | disclosed |
| US-20190248794-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2019-08-15 | — | — | US | disclosed |
| EP-3507291-A1 | FUSED BICYCLIC SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| WO-2018045276-A1 | FUSED BICYCLIC SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018045276-A1 | FUSED BICYCLIC SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180065971-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180065971-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180065971-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472363-B2 | SGC stimulators | GUCY1A2, PRKG1, GMPS | EPHB4 4398/4885KDR 848/4885TEK 2093/4885 |
| US-20250326761-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | EPHB4 4398/4885KDR 848/4885TEK 2093/4885 |
| US-20180065971-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | EPHB4 4398/4885KDR 848/4885TEK 2093/4885 |
| US-20220009937-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | EPHB4 4398/4885KDR 848/4885TEK 2093/4885 |
| US-20210177846-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | CS, COQ8A, GLS | EPHB4 4831/4885KDR 3935/4885TEK 4560/4885 |
| US-11731977-B2 | SGC stimulators | GUCY1A2, PRKG1, GMPS | EPHB4 4398/4885KDR 848/4885TEK 2093/4885 |
| US-20190248794-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | EPHB4 4398/4885KDR 848/4885TEK 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.